Purine News and Research

RSS

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA BioSciences, Inc. announced today that on April 26, 2010, DARA Therapeutics, a subsidiary of DARA BioSciences, and the Division of Cancer Prevention, National Cancer Institute (NCI), National Institutes of Health (NIH), entered into a Clinical Trials Agreement to advance the clinical study of KRN5500 for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) in patients with cancer. Under the terms of the collaboration, NCI will fund the studies and DARA will supply KRN5500 and placebo.

28 Apr 2010

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

HTDS - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

15 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

Metabolomics identifies biomarkers for periodontitis and gingivitis

...

30 Sep 2009

Research shows how p53 mutations link to high-grade breast cancer, poor outcomes

In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.

20 Apr 2009

From the works of Shakespeare to the genomes of viruses

What does uncovering the true authorship of plays attributed to Shakespeare have to do with identifying our genetic ancestors or classifying new life forms?

11 Feb 2009

Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout.

25 Nov 2008

Enzyme complex could be key to new cancer treatments

Penn State scientists are the first to observe in living cells a key step in the creation of adenine and guanine, two of the four building blocks that comprise DNA.

4 Apr 2008

Gene could spell new chapter in fight against gout

Researchers have found why some people are more susceptible to gout than others. The scientists looked at the genetic codes of more than 12,000 people after identifying a gene linked to uric acid levels in the blood.

10 Mar 2008

Researchers find crucial signal that switches on eye development

Researchers at the University of Warwick, funded by Wellcome Trust, have uncovered a crucial signal that switches on eye development.

24 Oct 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

Searching for the right pharmaceutical agent: survival as the indicator

Tumor cells divide fast. They thus require a high supply of components for their DNA, like purines. The biosynthesis of purines could now be a new point of attack for chemotherapy. However, without a natural model, the search for an inhibitor for a cellular process is like the proverbial search for a needle in a haystack. An American research team has developed a clever way to quickly conjure the desired "needle" out of the hay, presenting several candidates to act as starting points for the design of a purine synthesis inhibitor.

19 Apr 2005

Genetically engineered bugs to fight cancer

GENETICALLY engineered bacteria could become the latest weapons against cancer, Cancer Research UK scientists suggest in a study published today 22nd April 2004.

22 Apr 2004

Beer increases risk of gout

The first large epidemiological study to assess the age-old belief that alcohol consumption increases the risk of gout is published in the April 2004 issue of THE LANCET. A prospective study of nearly 50,000 men showed that beer drinking was more likely to be associated with gout than spirits; whereas moderate wine consumption was not linked to a risk of the disease.

16 Apr 2004

Cladribine Targeted to Become First Oral Therapy for Multiple Sclerosis

Serono and IVAX Corporation has announced positive results from two clinical trials with a new proprietary oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS). The study results showed that the formulation of oral cladribine which has been developed by Serono and IVAX has met the targets for an orally administered product, with blood levels of cladribine in the expected therapeutic range. Efficacy studies of oral cladribine in MS patients are planned to start late 2004.

23 Mar 2004